← Eichor
Study identifier: NCT07444632 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Phase1 Basket Trial Of CAR.70-Engineered IL15-Transduced With TGFBR2 Knock Out Cord Blood-Derived NK Cells For Relapsed/Refractory Lymphoid Malignancies

Condition: Lymphoid · Hodgkin Lymphoma  ·  Sponsor: M.D. Anderson Cancer Center

PhasePhase 1
Planned participants60
Who can joinAll sexes, 18 Years to 75 Years
Healthy volunteersNo

About this study

This is a phase 1 basket trial of TGFBR2 KO CAR27/IL-15 NK cells after lymphodepleting chemotherapy for patients with R/R B-NHL, HL, T-NHL or B-ALL.

This description comes directly from the study's public registry record.

Talk to the study team

Yago Nieto, MD, PHD  ·  (713) 794-1752  ·  ynieto@mdanderson.org

Always discuss trial participation with your own doctor first.

Locations (1)

The University of Texas M. D. Anderson Cancer CenterHouston, Texas, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07444632